Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Clinical practice. Low HDL cholesterol levels.

× No keyword cloud information.

40 in total

1. Canadian Cardiovascular Society position statement--recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease.

Authors: Ruth McPherson; Jiri Frohlich; George Fodor; Jacques Genest
Journal: Can J Cardiol Date: 2006-09 Impact factor: 5.223

Review 2. Management of dyslipidaemias.

Authors: Pathmaja Paramsothy; Robert Knopp
Journal: Heart Date: 2006-10 Impact factor: 5.994

Review 3. HDL cholesterol and cardiovascular outcomes: what is the evidence?

Authors: Melvyn Rubenfire; Robert D Brook
Journal: Curr Cardiol Rep Date: 2013-04 Impact factor: 2.931

4. Polyphenols and cholesterol efflux: is coffee the next red wine?

Authors: Megan F Burke; Amit V Khera; Daniel J Rader
Journal: Circ Res Date: 2010-03-05 Impact factor: 17.367

5. NASH resolution is associated with improvements in HDL and triglyceride levels but not improvement in LDL or non-HDL-C levels.

Authors: K E Corey; R Vuppalanchi; L A Wilson; O W Cummings; N Chalasani
Journal: Aliment Pharmacol Ther Date: 2014-11-28 Impact factor: 8.171

Review 6. Lifestyle Management of Diabetes: Implications for the Bone-Vascular Axis.

Authors: Silvia Pieralice; Francesca Vigevano; Rossella Del Toro; Nicola Napoli; Ernesto Maddaloni
Journal: Curr Diab Rep Date: 2018-08-18 Impact factor: 4.810

7. Obesity-related dyslipidemia associated with FAAH, independent of insulin response, in multigenerational families of Northern European descent.

Authors: Yi Zhang; Gabriele E Sonnenberg; Tesfaye Mersha Baye; Jack Littrell; Jennifer Gunnell; Ann DeLaForest; Erin MacKinney; Cecilia J Hillard; Ahmed H Kissebah; Michael Olivier; Russell A Wilke
Journal: Pharmacogenomics Date: 2009-12 Impact factor: 2.533

8. Differences in dyslipidemia between American and Italian women with polycystic ovary syndrome.

Authors: P A Essah; J E Nestler; E Carmina
Journal: J Endocrinol Invest Date: 2008-01 Impact factor: 4.256

Review 9. Does the addition of fibrates to statin therapy have a favorable risk to benefit ratio?

Authors: Eliot A Brinton
Journal: Curr Atheroscler Rep Date: 2008-02 Impact factor: 5.113

Review 10. Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors.

Authors: M John Chapman; Wilfried Le Goff; Maryse Guerin; Anatol Kontush
Journal: Eur Heart J Date: 2009-10-12 Impact factor: 29.983